- Home
- PCRX vs ECX Comparison
PCRX vs ECX Comparison
Compare PCRX & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ECX
- Stock Information
- Founded
- PCRX 2006
- ECX 2017
- Country
- PCRX United States
- ECX China
- Employees
- PCRX N/A
- ECX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ECX EDP Services
- Sector
- PCRX Health Care
- ECX Technology
- Exchange
- PCRX Nasdaq
- ECX Nasdaq
- Market Cap
- PCRX 1.2B
- ECX 589.5M
- IPO Year
- PCRX 2011
- ECX N/A
- Fundamental
- Price
- PCRX $23.22
- ECX $2.19
- Analyst Decision
- PCRX Buy
- ECX Strong Buy
- Analyst Count
- PCRX 8
- ECX 1
- Target Price
- PCRX $28.38
- ECX $3.20
- AVG Volume (30 Days)
- PCRX 569.8K
- ECX 2.7M
- Earning Date
- PCRX 07-29-2025
- ECX 08-07-2025
- Dividend Yield
- PCRX N/A
- ECX N/A
- EPS Growth
- PCRX N/A
- ECX N/A
- EPS
- PCRX N/A
- ECX N/A
- Revenue
- PCRX $702,772,000.00
- ECX $805,604,079.00
- Revenue This Year
- PCRX $7.54
- ECX $26.72
- Revenue Next Year
- PCRX $10.78
- ECX $30.34
- P/E Ratio
- PCRX N/A
- ECX N/A
- Revenue Growth
- PCRX 3.08
- ECX 19.98
- 52 Week Low
- PCRX $11.16
- ECX $0.76
- 52 Week High
- PCRX $27.64
- ECX $3.25
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- ECX 73.84
- Support Level
- PCRX $22.82
- ECX $1.62
- Resistance Level
- PCRX $24.36
- ECX $1.96
- Average True Range (ATR)
- PCRX 0.69
- ECX 0.15
- MACD
- PCRX -0.12
- ECX 0.05
- Stochastic Oscillator
- PCRX 17.09
- ECX 86.86
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.